These 37 synthetic biology companies raised $1.2B this quarter – Calvin Schmidt – Kevin Costa July 17, 2019

https://www.twistbioscience.com/?fbclid=IwAR2wX550OCKFamzsXQ_1bBHZl-f_ZnJw_wlgfizIZosHdvozHUZdBCVGn54

https://www.facebook.com/TwistBioscience/ https://synbiobeta.com/these-37-synthetic-biology-companies-raised-1-2b-this-quarter/

https://www.facebook.com/rodrigo.cal.37 http://www.twitter.com http://www.facebook.com http://www.google.com http://www.gmail.com http://www.youtube.com http://www.linkedin.com http://www.yahoo.com http://www.bol.com.br http://www.forbes.com http://www.harvard.edu https://www.nasa.gov/

http://www.facebook.com http://www.twitter.com http://www.linkedin.com http://www.gmail.com http://www.yahoo.com http://www.bol.com.br http://www.forbes.com http://www.youtube.com

Do the downloads!! Share!! The diffusion of very important information and knowledge is essential for the world progress always!! Thanks!!

  • – > Mestrado – Dissertation – Tabelas, Figuras e Gráficos – Tables, Figures and Graphics – ´´My´´ Dissertation @ #Innovation #energy #life #health #Countries #Time #Researches #Reference #Graphics #Ages #Age #Mice #People #Person #Mouse #Genetics #PersonalizedMedicine #Diagnosis #Prognosis #Treatment #Disease #UnknownDiseases #Future #VeryEfficientDrugs #VeryEfficientVaccines #VeryEfficientTherapeuticalSubstances #Tests #Laboratories #Investments #Details #HumanLongevity #DNA #Cell #Memory #Physiology #Nanomedicine #Nanotechnology #Biochemistry #NewMedicalDevices #GeneticEngineering #Internet #History #Science #World

Pathol Res Pract. 2012 Jul 15;208(7):377-81. doi: 10.1016/j.prp.2012.04.006. Epub 2012 Jun 8.

The influence of physical activity in the progression of experimental lung cancer in mice

Renato Batista Paceli 1Rodrigo Nunes CalCarlos Henrique Ferreira dos SantosJosé Antonio CordeiroCassiano Merussi NeivaKazuo Kawano NagaminePatrícia Maluf Cury


Impact_Fator-wise_Top100Science_Journals

GRUPO_AF1 – GROUP AFA1 – Aerobic Physical Activity – Atividade Física Aeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto

GRUPO AFAN 1 – GROUP AFAN1 – Anaerobic Physical Activity – Atividade Física Anaeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto

GRUPO_AF2 – GROUP AFA2 – Aerobic Physical Activity – Atividade Física Aeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto

GRUPO AFAN 2 – GROUP AFAN 2 – Anaerobic Physical Activity – Atividade Física Anaeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto

Slides – mestrado – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto

CARCINÓGENO DMBA EM MODELOS EXPERIMENTAIS

DMBA CARCINOGEN IN EXPERIMENTAL MODELS

Avaliação da influência da atividade física aeróbia e anaeróbia na progressão do câncer de pulmão experimental – Summary – Resumo – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto

https://pubmed.ncbi.nlm.nih.gov/22683274/

Abstract

Lung cancer is one of the most incident neoplasms in the world, representing the main cause of mortality for cancer. Many epidemiologic studies have suggested that physical activity may reduce the risk of lung cancer, other works evaluate the effectiveness of the use of the physical activity in the suppression, remission and reduction of the recurrence of tumors. The aim of this study was to evaluate the effects of aerobic and anaerobic physical activity in the development and the progression of lung cancer. Lung tumors were induced with a dose of 3mg of urethane/kg, in 67 male Balb – C type mice, divided in three groups: group 1_24 mice treated with urethane and without physical activity; group 2_25 mice with urethane and subjected to aerobic swimming free exercise; group 3_18 mice with urethane, subjected to anaerobic swimming exercise with gradual loading 5-20% of body weight. All the animals were sacrificed after 20 weeks, and lung lesions were analyzed. The median number of lesions (nodules and hyperplasia) was 3.0 for group 1, 2.0 for group 2 and 1.5-3 (p=0.052). When comparing only the presence or absence of lesion, there was a decrease in the number of lesions in group 3 as compared with group 1 (p=0.03) but not in relation to group 2. There were no metastases or other changes in other organs. The anaerobic physical activity, but not aerobic, diminishes the incidence of experimental lung tumors.

    • SEARCH

    • SEARCH
synthetic biology companies

A strong second quarter put the synthetic biology industry on track to match 2019’s record breaking year of investment, with about one-third more companies getting a piece of the pie. Image: SynBioBeta.Home » Featured Slider » These 37 synthetic biology companies raised $1.2B this quarterFEATURED SLIDERFUNDING & INVESTMENTS

These 37 synthetic biology companies raised $1.2B this quarter

Calvin SchmidtKevin CostaJuly 17, 2019

Crunchbase reports that startup funding is flat this quarter. But the synthetic biology industry doesn’t seem to have gotten the memo.

SynBioBeta released its Synthetic Biology Investment Report for this quarter, detailing the top funded companies in the space, newly funded companies, and investment trends for the past several years. What follows are some highlights from the report — download the full report for all the details.

Are we hot or not?

After the first quarter, the field was on track to set a record for the total number of investment deals, although the total amount of money being invested was not projected to beat out 2018’s staggering sum of $3.8 billion. But the second quarter of the year was the best on record, putting even better than the first, demonstrating that investor interest in both the public and private markets is strong and growing.

Through the first half of 2019, 65 synthetic biology companies raised $1.9 billion in funding. Both of these numbers would be higher than any full year except for last year, which goes to show just how fast the field is growing. If investing keeps up at this pace, 2019 will see 33% more investment rounds worth about the same as last year — $3.8 billion.

Synthetic Biology Investments

The Class of 2019: Reimagining pharma

Seven of the 37 companies funded this quarter are receiving their first round of investment, and of those seven all but one is related to therapeutic applications. This may be an indication that the tools and technologies of synthetic biology are enabling small, innovative, fast-moving companies to reimagine pharma and pursue market opportunities that were previously inaccessible. More importantly, patients with rare and undertreated diseases also stand to benefit, as small therapeutic markets become more economically viable for both small and large companies alike to pursue.

synthetic biology companies

More companies are getting a piece of the pie

During a SynBioBeta 2018 investor panel (available online), Alicia Jackson of Genoa Ventures remarked that there is an unlimited amount of money in the world now, but that there is a very limited supply of great entrepreneurs. Despite that, 2019 is on track to fund about one-third more rounds than last year, suggesting that investor support for synthetic biology entrepreneurs and their technology is still high.

Synthetic Biology Investments

Overall, raising a large amount of money in a year is related more to having a few huge fundraising rounds rather than having a large number of companies raise. 2018 had a few of these, like Moderna and Zymergen’s combined $1 billion, which contributed to the large leap in dollars raised. Though Impossible Foods had a funding round in this range ($300 million), we will need several more rounds like this in order to continue setting records for funds raised.

synthetic biology companies

As with newly funded companies, therapeutics companies are strongly represented among the top-funded companies in Q2.

What does it all mean?

Crunchbase reports that, in the broader North American investment market, there are a lot of data indicators pointing in different directions. IPOs were super strong, deal volume is up somewhat, but investment totals were flat. In general, the funding climate appears to be holding firm.

The synthetic biology industry had a record quarter, with investors remaining bullish about the ability of biology to solve important problems, create better products, and drive new markets. And post-IPO performance has also been solid, with companies like Twist and Beyond Meat maintaining valuations well above their initial offering price.

The continued growth of the industry is linked to the broader market, and could be  significantly impacted by social and political factors such as a Green New Deal, the adoption of a federal roadmap for strategic investment in synthetic biology, or even our ability as a field to engage with the public and earn trust for bioengineered products. Time will only tell if any or all of these things will come to pass. For the time being, though, it seems the investment community is signalling full speed ahead.

To learn what parts of the synbio stack are hot right now, who’s investing, and geographic funding trends, download the full report.

Download the report

3

Calvin Schmidt

Calvin Schmidt

Calvin Schmidt is a Ph.D. candidate in the laboratory of Professor Christina Smolke in the Department of Bioengineering at Stanford University. His research interests involve the use of machine learning to automate the design of biological systems.

He believes that new biological technologies will have a huge impact on fields ranging from healthcare to chemical production to agriculture. He’s looking to connect with entrepreneurs and investors in these fields to learn and provide expertise.VIEW ALL POSTS

Kevin Costa

Kevin Costa

As Editor and Program Manager, Kevin leads SynBioBeta’s digital media content and works with customers and partners to build a world-class community of innovators. Before joining SynBioBeta, Kevin managed the Synthetic Biology Engineering Research Center. His interests include public engagement, science writing, community building, and bikes!VIEW ALL POSTSClick here to join our weekly newsletter. We want to hear what you think about this article. Got a tip for our news team? Write to editorial@synbiobeta.com.

You may also like

Biosecurity today for the economic security of tomorrow

Benchling Raises $34.5M Series C To Fuel Life Sciences R&D

Cambridge Consultants

One year later: how far have we come toward building the business of biodesign?

SynbiCITE

Getting started: Building synthetic biology companies in the US and the UK

Editor’s picks

UK synthetic biology
A Game of Genomes: UK Synthetic Biology Research Centers
industrial microbes
GMO doesn’t cut it: Why synthetic biology needs better labeling of industrial microbes
Synthace
Closing the loop with computer aided biology
SynBioBeta Webinar “CRISPR Enabled Trackable Engineering (CREATE): Bringing Genome Engineering to the Bench”
Five ways buildings of the future will use biotech to become living things
apoptosis
Synthetic biology news from the lab bench #4
How chemical-sensing plants may help secure a safe, healthy future
protein design
Protein design 101: An introduction to protein design for synthetic biology – with Alexandre Zanghellini
Pseudofreeze
Tackling the future of sustainability at the 2019 Biodesign Challenge Summit
NanoRacks
Microgravity: biomedicine’s next frontier
Kiersten Stead
Rethinking sustainable agriculture: creative solutions from unexpected places
Light wall moss leaf
Synthetic biology news from the lab bench #3
Biosecurity today for the economic security of tomorrow
Cambridge Consultants
One year later: how far have we come toward building the business of biodesign?
SynbiCITE
Getting started: Building synthetic biology companies in the US and the UK
Synthetic Biology Investing
Synthetic Biology Investing in an Age of Open Platforms
Duane Clark
Better than Disneyland: Why Duane Clark believes space habitation is something worth investing in
Adam Arkin
How biomanufacturing can make living on Mars a reality
UK synthetic biology
A Game of Genomes: UK Synthetic Biology Research Centers
industrial microbes
GMO doesn’t cut it: Why synthetic biology needs better labeling of industrial microbes
Synthace
Closing the loop with computer aided biology
SynBioBeta Webinar “CRISPR Enabled Trackable Engineering (CREATE): Bringing Genome Engineering to the Bench”
Five ways buildings of the future will use biotech to become living things
apoptosis
Synthetic biology news from the lab bench #4
How chemical-sensing plants may help secure a safe, healthy future
protein design
Protein design 101: An introduction to protein design for synthetic biology – with Alexandre Zanghellini
Pseudofreeze
Tackling the future of sustainability at the 2019 Biodesign Challenge Summit
NanoRacks
Microgravity: biomedicine’s next frontier
Kiersten Stead
Rethinking sustainable agriculture: creative solutions from unexpected places
Light wall moss leaf
Synthetic biology news from the lab bench #3
Biosecurity today for the economic security of tomorrow
Cambridge Consultants
One year later: how far have we come toward building the business of biodesign?
SynbiCITE
Getting started: Building synthetic biology companies in the US and the UK
Synthetic Biology Investing
Synthetic Biology Investing in an Age of Open Platforms
Duane Clark
Better than Disneyland: Why Duane Clark believes space habitation is something worth investing in
Adam Arkin
How biomanufacturing can make living on Mars a reality
UK synthetic biology
A Game of Genomes: UK Synthetic Biology Research Centers
industrial microbes
GMO doesn’t cut it: Why synthetic biology needs better labeling of industrial microbes
Synthace
Closing the loop with computer aided biology
SynBioBeta Webinar “CRISPR Enabled Trackable Engineering (CREATE): Bringing Genome Engineering to the Bench”
Five ways buildings of the future will use biotech to become living things
apoptosis
Synthetic biology news from the lab bench #4

Synthetic Biology Reports

Job opportunities

Biotech Research Scientist for DNA Synthesis Platform – DNA Script, Paris, FranceScientist/Sr. Scientist: Cell Biology, Microbe – Inscripta, Boulder, COProtein Evolution and Engineering Scientist: Bioheuris, St. Louis, MOApplications Scientist, Data Science: Inscripta, Pleasanton, CAField Applications Scientist – West, Inscripta, San Francisco, CA

More

Videos

Labcyte
SynBioBeta Deep Dive – Amyris and Labcyte: Increasing strain construction efficiency and reducing reaction volumes
SynBioBetaLive RIffyn
SynBioBetaLive! – Lab data to machine learning in 30 seconds with Riffyn
Opentrons
SynBioBetaLive! Let a thousand foundries bloom with Opentrons
SynBioBetaLive! with P&G
Synthetic Biology Annual Investment Report (2018)
What’s your Bio Strategy? Biopharma and Healthcare Industry (2018)
Tierra Biosciences
SynBioBeta Deep Dive webinar with Tierra Biosciences and Labcyte
Bio is not another app
Watch Panel “Bio is not another app: Investing in what’s important” at SynBioBeta 2018
SynbiCITE
SynbiCITE webinar: Global trends and business opportunities in synbio
Labcyte
SynBioBeta Deep Dive – Amyris and Labcyte: Increasing strain construction efficiency and reducing reaction volumes
SynBioBetaLive RIffyn
SynBioBetaLive! – Lab data to machine learning in 30 seconds with Riffyn
Opentrons
SynBioBetaLive! Let a thousand foundries bloom with Opentrons
SynBioBetaLive! with P&G
Synthetic Biology Annual Investment Report (2018)
What’s your Bio Strategy? Biopharma and Healthcare Industry (2018)
Tierra Biosciences
SynBioBeta Deep Dive webinar with Tierra Biosciences and Labcyte
Bio is not another app
Watch Panel “Bio is not another app: Investing in what’s important” at SynBioBeta 2018
SynbiCITE
SynbiCITE webinar: Global trends and business opportunities in synbio
Labcyte
SynBioBeta Deep Dive – Amyris and Labcyte: Increasing strain construction efficiency and reducing reaction volumes
SynBioBetaLive RIffyn
SynBioBetaLive! – Lab data to machine learning in 30 seconds with Riffyn
Opentrons
SynBioBetaLive! Let a thousand foundries bloom with Opentrons
SynBioBeta Logo White

SynBioBeta is the leading community of innovators, investors, engineers, and thinkers who share a passion for using synthetic biology to build a better, more sustainable universe. We’re dedicated to telling the stories of the people and companies involved, building their networks, and helping them grow.

Privacy PolicyCookie Policy

Join our weekly newsletter

SIGN UP

Copyright © SynBioBeta LLC 2019. All Rights Reserved.

4 Comments

  1. I really like your article. It’s evident that you have a lot knowledge on this topic. Your points are well made and relatable. Thanks for writing engaging and interesting material.

    Like

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s